Physician profile
Jerry Weed
NPI 1275570897
$6,026.26
in general payments reported to CMS, 2019-2025
34 companies · $2,843 in 2025
The $2,843 reported for 2025 was more than what 93% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $203 · 2021: $304 · 2022: $227 · 2023: $871 · 2024: $675 · 2025: $2,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,296 · Food and Beverage: $2,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,296.04 |
| Food and Beverage | $2,092.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $2,493.87 | 2022-2025 | Pico, Collagenase Santyl, Grafix |
| International Life Sciences | $643.13 | 2023 | |
| Horizon Therapeutics Plc | $382.52 | 2019-2022 | |
| Kerecis Limited | $358.83 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Ortho Solutions INC | $343.60 | 2019 | |
| Paratek Pharmaceuticals, INC. | $187.74 | 2022-2024 | Nuzyra |
| Acera Surgical, INC. | $156.50 | 2025 | Restrata Wound Matrix |
| Paragon 28, INC. | $147.73 | 2024 | Hammertube Sterile Implant Kits |
| Bard Peripheral Vascular, INC. | $133.77 | 2024 | Venclose Maven Catheter |
| Metric Medical Devices, INC. | $128.58 | 2020 | |
| Amgen INC. | $123.97 | 2025 | Krystexxa |
| Penumbra, INC. | $120.82 | 2024 | Penumbra System |
| Organogenesis INC. | $111.07 | 2021 | |
| Kci USA, INC. | $108.43 | 2019 | |
| Access Pro Medical, LLC | $70.91 | 2023 | Matriderm |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $62.44 | 2022-2023 | Exogen Ultrasound Bone Healing System |
| Ebi, LLC | $48.73 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Highridge Medical LLC | $48.73 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Daiichi Sankyo INC. | $38.28 | 2019 | |
| Zyla Life Sciences, INC. | $33.86 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $32.57 | 2022-2025 | Exparel, Iovera |
| Novo Nordisk INC | $27.02 | 2019-2024 | Ozempic, Rybelsus |
| Aroa Biosurgery Incorporated | $23.70 | 2024 | |
| Melinta Therapeutics, LLC | $22.64 | 2019 | |
| Averitas Pharma INC. | $20.83 | 2024 | Qutenza |
| Globus Medical, INC. | $20.68 | 2025 | Senza |
| Mimedx Group, INC. | $20.29 | 2024 | |
| Lilly USA, LLC | $19.25 | 2022 | |
| Djo, LLC | $18.89 | 2019 | |
| Orthofix Medical, INC. | $18.50 | 2025 | Physio-Stim |
| Bayer Healthcare Pharmaceuticals INC. | $15.88 | 2021 | |
| Medtronic, INC. | $14.65 | 2023 | Venaseal |
| Zimvie INC. | $14.27 | 2023 | |
| Cashflow Solutions, LLC | $13.58 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Weed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.